David Rosen has this month joined US-based healthcare venture capital firm MPM Capital as an entrepreneur-in-residence.
He was previously the head of corporate outlicensing at New York-listed Pfizer for 11 years where he took non-core assets at the drugs company and span them out to other strategic and financial investors. His move comes as Pfizer’s research and development head, Martin Mackay, joined peer AstraZeneca leaving Mikael Dolsten in charge.